Evidence map›Paper›PMID 34570807›Full record

ArticlePLoS neglected tropical diseases2021

Implementation of mass drug administration for neglected tropical diseases in Guinea during the COVID-19 pandemic.

Fatoumata Sakho, Christelly Flore Badila, Benoit Dembele, Aissatou Diaby, Abdoul Karim Camara, Lamine Lamah, Steven D Reid, Angel Weng, Brian B Fuller, Katherine A Sanchez and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Fatoumata SakhoNational Neglected Tropical Disease Control Program, Ministry of Health, Conakry, Guinea.ORCID 0000-0003-3819-9361
Christelly Flore BadilaGuinea Office, Helen Keller International, Conakry, Guinea.ORCID 0000-0001-9768-3239
Benoit DembeleRegional office for Africa, Helen Keller International, Dakar, Senegal.ORCID 0000-0001-6712-310X
Aissatou DiabyNational Neglected Tropical Disease Control Program, Ministry of Health, Conakry, Guinea.
Abdoul Karim CamaraGuinea Office, Helen Keller International, Conakry, Guinea.ORCID 0000-0002-5222-8061
Lamine LamahGuinea Office, Helen Keller International, Conakry, Guinea.
Steven D ReidHeadquarters, Helen Keller International, New York, New York, United States of America.ORCID 0000-0002-8585-4894
Angel WengHeadquarters, Helen Keller International, New York, New York, United States of America.ORCID 0000-0001-5928-1570
Brian B FullerHeadquarters, Helen Keller International, New York, New York, United States of America.ORCID 0000-0001-5865-2528
Katherine A SanchezFamily Health International 360, Washington DC, Maryland, United States of America.ORCID 0000-0003-1713-4809
Achille KaboreFamily Health International 360, Washington DC, Maryland, United States of America.
Yaobi ZhangRegional office for Africa, Helen Keller International, Dakar, Senegal.
Angela WeaverHeadquarters, Helen Keller International, New York, New York, United States of America.
Helen Keller International · USFamily Health International 360 · USMinistry of Health and Public Hygiene · GN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGuinea reported its first case of COVID-19 on March 12, 2020. Soon thereafter, a national state of emergency was declared, all land borders were closed, schools were shut down, and public gatherings were limited. Many health activities, including field-based activities targeting neglected tropical diseases (NTDs), were paused. The World Health Organization (WHO) issued updated guidance on the resumption of NTD field-based activities on July 27, 2020. In response, the Guinea Ministry of Health (MoH) and its partners planned and resumed mass drug administration (MDA) in mid-August to September 2020 in 19 health districts. METHODOLOGY/PRINCIPAL

findingsA risk-benefit assessment was conducted to identify potential risks associated with the MDA in the COVID-19 context. Following this assessment, a risk mitigation plan with barrier measures was developed to guide MDA implementation. These measures included COVID-19 testing for all national staff leaving Conakry, mask wearing, social distancing of two meters, and hand washing/sanitizing. A checklist was developed and used to monitor compliance to risk mitigation measures. Data on adherence to risk mitigation measures were collected electronically during the MDA. A total of 120 checklists, representing 120 community drug distributor (CDD) teams (two CDDs per team) and 120 households, were completed. Results indicated that washing or disinfecting hands was practiced by 68.3% of CDD teams, compared to 45.0% among households. Face masks to cover the mouth and nose were worn by 79.2% of CDD teams, while this was low among households (23.3%). In 87.5% of households, participants did not touch the dose pole and in 88.3% of CDD teams, CDDs did not touch the hands of the participants while giving the drugs. A large majority of CDD teams (94.2%) and household members (94.2%) were willing to participate in the MDA despite the pandemic. The epidemiological coverage was ≥65% for lymphatic filariasis, onchocerciasis and soil-transmitted helminths in 10 out of 19 HDs and ≥75% for schistosomiasis for school-aged children in 7 out of 11 HDs. CONCLUSIONS/SIGNIFICANCE: Guinea was one of the first countries in Africa to resume MDA activities during the COVID-19 pandemic without causing an observed increase of transmission. The development of a risk mitigation plan and a method to monitor adherence to barrier measures was critical to this unprecedented effort. The rapid incorporation of COVID-19 barrier measures and their acceptance by CDDs and household members demonstrated both the adaptability of the National NTD Program to respond to emerging issues and the commitment of the MoH to implement NTD programs.

Indexed as

COVID-19Mass Drug AdministrationAntiparasitic AgentsCOVID-19 TestingElephantiasis, FilarialGovernment ProgramsGuideline AdherenceGuineaHumansNeglected DiseasesOnchocerciasisPandemicsRisk AssessmentSARS-CoV-2SchistosomiasisSoilAntiparasitic AgentsSoil

Identifiers

PMID34570807
PMCPMC8496865
OpenAlexW3204199675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.